GlassScriptPhysician profile
Chandler Bray Graham
NPI 1285414151
$5,485.74
in general payments reported to CMS, 2019-2025
26 companies · $3,044 in 2025
The $3,044 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $216 · 2024: $2,226 · 2025: $3,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,453 · Education: $32.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,453.21 |
| Education | $32.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,550.97 | 2023-2025 | |
| Janssen Biotech, INC. | $697.92 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Ardelyx, INC. | $455.58 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $425.52 | 2023-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $350.41 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $263.54 | 2023-2025 | Voquezna |
| Qol Medical, LLC | $175.87 | 2024-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $173.57 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $163.33 | 2024-2025 | Rebyota |
| Novo Nordisk INC | $158.39 | 2025 | Wegovy |
| Lilly USA, LLC | $140.27 | 2024-2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.23 | 2023-2025 | Xifaxan, Trulance |
| Aimmune Therapeutics, INC. | $121.46 | 2024-2025 | Zenpep, Vowst |
| Gilead Sciences, INC. | $112.19 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $86.16 | 2024-2025 | Dupixent |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $85.59 | 2024 | Watchman Flx |
| Pfizer INC. | $80.54 | 2024-2025 | |
| Celltrion USA INC. | $66.96 | 2024-2025 | Vegzelma, Zymfentra |
| Merck Sharp & Dohme LLC | $61.35 | 2023-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $52.05 | 2024-2025 | |
| Neuraxis, INC. | $35.82 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $24.39 | 2025 | Iqirvo |
| Daiichi Sankyo INC. | $22.78 | 2025 | Injectafer |
| Biocon Biologics INC | $19.73 | 2024 | Hulio |
| Braintree Laboratories, INC. | $16.51 | 2024 | Sutab, Suflave |
| Exact Sciences Corporation | $13.61 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandler Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.